{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:19:01Z","timestamp":1778253541877,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Angioimmunoblastic T-cell lymphoma (AITL), a highly aggressive peripheral T-cell lymphoma (PTCL), carries a poor prognosis in elderly patients due to frequent relapse and limited salvage options after multiline therapy. We present the case of an 80-year-old woman with relapsed\/refractory (R\/R) AITL who relapsed after CHOP and exhibited resistance to the following sequential therapies: second-line chidamide plus COP and third-line chidamide with mitoxantrone hydrochloride liposome. Molecular analysis revealed <jats:italic>DNMT3A<\/jats:italic> and <jats:italic>IDH2<\/jats:italic> mutations, reflecting disease complexity. Salvage therapy with linperlisib, a selective PI3K\u03b4 inhibitor, combined with gemcitabine\/oxaliplatin induced sustained partial remission, followed by linperlisib maintenance. The regimen demonstrated exceptional safety, with no grade \u22652 toxicities, even in this frail population. This case highlights the dual role of linperlisib as an effective and well-tolerated therapy for elderly R\/R AITL patients who have exhausted prior lines. By precisely targeting PI3K\u03b4, our findings offer critical real-world evidence to address the unmet need for safe salvage strategies in this vulnerable population.<\/jats:p>","DOI":"10.3389\/fphar.2025.1554501","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:30:29Z","timestamp":1747287029000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful treatment of an elderly patient with relapsed\/refractory angioimmunoblastic T-cell lymphoma with the PI3K\u03b4 inhibitor linperlisib: a Case Report"],"prefix":"10.3389","volume":"16","author":[{"given":"Ming-Qiang","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Hui","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world Health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.medj.2024.07.007","article-title":"A prospective phase 2 study of combination epigenetic therapy against relapsed\/refractory peripheral T cell lymphoma","volume":"5","author":"Ding","year":"2024","journal-title":"Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1080\/10428194.2024.2390567","article-title":"New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis","volume":"65","author":"Frutos D\u00edaz-Alejo","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood-2020-141752","article-title":"Safety and efficacy of mitoxantrone hydrochloride liposome in patients with relapsed or refractory peripheral T-cell lymphoma and extranodal NK\/T-Cell lymphoma: a prospective, single-arm, open-label, multi-center, phase II clinical trial","volume":"136","author":"Gao","year":"2020","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2019-126481","article-title":"Safety and efficacy of mitoxantrone hydrochloride liposome in patients with relapsed or refractory peripheral T-cell lymphoma and extranodal NK\/T-Cell lymphoma: a multicenter, single-arm, open-label, phase 2 clinical trial","volume":"134","author":"Huang","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-021-01140-z","article-title":"Phase 1 clinical trial of the PI3K\u03b4 inhibitor YY-20394 in patients with B-cell hematological malignancies","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1158\/1078-0432.CCR-24-1194","article-title":"A phase Ib study of linperlisib in the treatment of patients with relapsed and\/or refractory peripheral T-cell lymphoma","volume":"30","author":"Jin","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.3390\/curroncol28060456","article-title":"Recent advances in diagnosis and therapy of angioimmunoblastic T cell lymphoma","volume":"28","author":"Mohammed Saleh","year":"2021","journal-title":"Curr. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/1078-0432.CCR-22-2939","article-title":"The oral PI3K\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial","volume":"29","author":"Wang","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1002\/cam4.5248","article-title":"Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China","volume":"12","author":"Wei","year":"2023","journal-title":"Cancer Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41408-017-0047-2","article-title":"Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways","volume":"8","author":"Willemsen","year":"2018","journal-title":"Blood Cancer J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e92585","DOI":"10.1371\/journal.pone.0092585","article-title":"No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40164-021-00224-3","article-title":"Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas","volume":"10","author":"Yoon","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.21147\/j.issn.1000-9604.2022.04.09","article-title":"Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation","volume":"34","author":"Zou","year":"2022","journal-title":"Chin. J. Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1554501\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:30:29Z","timestamp":1747287029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1554501\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":26,"alternative-id":["10.3389\/fphar.2025.1554501"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1554501","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"article-number":"1554501"}}